Browse resources

Disease: Respiratory syncytial virus (RSV)

Total results with these characteristics: 43

Page 2 of 2  
‹ prev.
1
2

Respiratory Syncytial Virus Disease in Infants Despite Prior Administration of Antigenic Inactivated Vaccine

This article, published in the American Journal of Epidemiology, details studies conducted to determine the ability of a formalin inactivated vaccine candidate to protect against respiratory syncytial virus (RSV) disease. Results from the study …

Author: Kim HW, Canchola JG, Brandt CD, et al.

Published: 1969

Respiratory Syncytial Virus Infection (RSV)

This web page provides a wide spectrum of information about respiratory syncytial virus (RSV) in the United States. It offers a general overview of the disease as well as clinical, research, and surveillance information. Specific topics include, …

Author: US Centers for Disease Control and Prevention

Respiratory Syncytial Virus Vaccine Development

Despite half a century of dedicated research, there remains no licensed vaccine product against respiratory syncytial virus (RSV). This article, published in Expert Review of Vaccines, describes efforts to harness innate and adaptive immune …

Author: Hurwitz JL

Published: 2011

Respiratory Virus Immunization: A Field Trial of Two Inactivated Respiratory Virus Vaccines; an Aqueous Trivalent Parainfluenza Virus Vaccine and an Alum-Precipitated Respiratory Syncytial Virus Vaccine

This article, published in the American Journal of Epidemiology, describes a field trial conducted to evaluate an inactivated, alum-precipitated respiratory syncytial virus (RSV) vaccine and an aqueous trivalent parainfluenza virus vaccine. Study …

Author: Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G

Published: 1969

A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease

Administration of a formalin-inactivated vaccine against respiratory syncytial virus (RSV) to children in the 1960s resulted in increased morbidity and mortality in vaccine recipients who subsequently contracted RSV. This incident precluded …

Author: Polack FP, Teng MN, Collins PL, et al.

Published: 2002

RSV Vaccine Snapshot

This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine technology landscape, in the effort to track the development of RSV vaccine candidates and provide a summary of all the various vaccine approaches being worked on …

Author: PATH

Published: 2013

Soluble Respiratory Syncytial Virus Fusion Protein in the Fully Cleaved, Pretriggered State is Triggered by Exposure to Low-Molarity Buffer

This article, published by the Journal of Virology, discusses research conducted to study the triggering mechanism of a soluble respiratory syncytial virus fusion protein. ABSTRACT ONLY: (Learn how users in developing countries can gain free access …

Author: Chaiwatpongsakorn S, Epand RF, Collins PL, Epand RM, Peeples ME

Published: 2011

Soluble Respiratory Syncytial Virus Fusion Protein in the Fully Cleaved, Pretriggered State is Triggered by Exposure to Low-Molarity Buffer

The respiratory syncytial virus (RSV) fusion (F) protein is a major target for vaccine and small-molecule antiviral drug development related to this virus. The authors of this article, published in the Journal of Virology, describe how they produced …

Author: Chaiwatpongsakorn S, Epand RF, Collins PL, Epand RM, Peeples ME

Published: 2011

State of the Art of New Vaccines: Research and Development

This document analyzes research and development activities for vaccines against infectious diseases of public health importance. Disease groups covered include diarrheal disease, sexually transmitted diseases, respiratory infections, bacterial …

Author: World Health Organization

Published: 2006

Structural Basis for Immunization With Postfusion Respiratory Syncytial Virus Fusion F Glycoprotein (RSV F) to Elicit High Neutralizing Antibody Titers

Respiratory syncytial virus (RSV) vaccine candidates based on a chief RSV neutralization antigen, the fusion (F) glycoprotein, have foundered due to problems with stability, purity, reproducibility, and potency. The authors of this article, …

Author: Swanson KA, Settembre EC, Shaw CA, et al.

Published: 2011

Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex With Neutralizing Antibody 101F

Currently there is no effective vaccine against respiratory syncytial virus (RSV), but passive prophylaxis with neutralizing antibodies reduces hospitalizations. To investigate the mechanism of antibody-mediated RSV neutralization, the authors of …

Author: McLellan JS, Chen M, Chang JS, et al.

Published: 2010

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

This article, published in Science, describes research to characterize the respiratory syncytial virus (RSV) fusion glycoprotein prefusion conformation, which is the target of most RSV-neturalizing activity in human sera. ABSTRACT ONLY: (Learn how …

Author: McLellan JS, Chen M, Leung S, et al

Published: 2013

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

This article, published in Science, describes research to engineer a respiratory synctial virus (RSV) viral antigen that focuses on antigenic site ø, a metastable site specific to the prefusion state of the RSV fusion glycoprotein. ABSTRACT ONLY: …

Author: McLellan JS, Chen M, Joyce MG, et al.

Published: 2013

Surveillance for Respiratory Syncytial Virus in CDC's Global Disease Detection Network: Epidemiology, Disease Burden and Clinical Characteristics

This supplement to The Journal of Infectious Diseases features articles on respiratory syncytial virus (RSV) surveillance data through the US Centers for Disease Control and Prevention's (CDC's) Global Disease Detection Network . The 12 articles …

Author: Iwane MK, Garnon EC, Gerber SI, eds.

Published: 2013

Vaccine Development Global Program

This website provides information about the work of PATH’s Vaccine Development Global Program to improve the health of people, especially infants and children living in low-income countries, by accelerating the development of vaccines …

Author: PATH

Vaccine-Enhanced Respiratory Syncytial Virus Disease in Cotton Rats Following Immunization with Lot 100 or a Newly Prepared Reference Vaccine

A formalin-inactivated respiratory syncytial virus vaccine was used to immunize infants in the mid-1960s; when these children later were naturally infected by the virus they developed markedly accentuated disease, and two died. For the …

Author: Prince GA, Curtis SJ, Yim KC, Porter DD

Published: 2001

Vaccines for the Future

This quarterly e-newsletter provides an update on PATH’s efforts to accelerate the development of innovative, safe, effective, and affordable vaccines against the leading causes of childhood deaths in developing-world populations, pneumonia …

Author: PATH

Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis

The authors of this article, published in the Journal of Virology, discuss the contributions of viral versus various host factors to respiratory syncytial virus (RSV) pathogenesis. The authors conclude that a better understanding of the …

Author: Collins PL, Graham BS

Published: 2008

Page 2 of 2  
‹ prev.
1
2